SAREPTA THERAPEUTICS, INC. (SRPT)
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
📈 **POSITIVE** • Medium confidence analysis (79%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business